Page View Count : 97863
INVO
INVO Bioscience
( )
vista's key points
- INVO is commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective & affordable treatment for patients diagnosed with infertility.
- INVOcell addresses key industry challenges regarding cost & capacity constraints: ability to help treat underserved patients as an alternative to traditional in vitro- fertilization (IVF)
- ~$15-$18 Billion global infertility industry growing ~8-10% annually.
- Vast underserved global market ~95%+ of infertile individuals go untreated: significant unmet market opportunity.
- U.S. commercialization agreement in January 2019 with Ferring Pharmaceuticals a multi-national firm and significant player in the global fertility drug market.
- Distribution agreements in eight countries located within Africa, Asia, Europe and the Middle East.
- Seeking to establish the initial 1-2 JV agreements, in Q1, for INVO-only clinics within the U.S. market.
company profile
vista's view
INVO Bioscience successfully conducted a public offering in November 2020, raising net proceeds of approximately $11.6 million at $3.20/share while uplisting the company onto the NASDAQ market. These moves strengthened their balance sheet & their position to execute on their commercialization efforts in the US and around the world. Analysts...
Read MoreINVO Bioscience successfully conducted a public offering in November 2020, raising net proceeds of approximately $11.6 million at $3.20/share while uplisting the company onto the NASDAQ market. These moves strengthened their balance sheet & their position to execute on their commercialization efforts in the US and around the world. Analysts from both Colliers International Securities and Roth Capital Partners initiated coverage on INVO in December 2020 with BUY ratings and price targets ranging from $5-$5.75/share. Upcoming milestones and/or new distributor & joint venture agreements, opening of INVO-only clinics with existing partners in the US and abroad, & successfully receiving the nod from the FDA for 5-day labelling, which alone would would allow INVO to achieve a milestone payment of $3 Million from their US partner Ferring Pharmaceuticals.
Read LessPage View Count : 97863
exclusive content
Vista Partners creates exclusive content based on the ongoing research of companies included in the VP Watchlist.
vp watchlist
The VP Watchlist contains current coverage companies that deserve consideration for short term and long term portfolio additions.
recent news
-
INVO Bioscience Expands Distribution of INVOcell Into...
15 January 2021 | 1:30 pm
-
INVO Bioscience Management Letter to Shareholders
7 January 2021 | 2:00 pm
-
INVO Bioscience and idsMED Group Enter Distribution...
25 November 2020 | 2:00 pm